Evotec SE (EVO)
Pre-Market:
| Previous Close | 4.7700 |
| Open | 4.8800 |
| Bid | 4.8500 x 200 |
| Ask | 4.8900 x 200 |
| Day's Range | 4.8300 - 4.9600 |
| 52 Week Range | 4.7700 - 13.4900 |
| Volume | |
| Avg. Volume | 142,077 |
| Market Cap | 1.738B |
| Beta (5Y Monthly) | 1.17 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2800 |
| Earnings Date | Aug 14, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.64 |
ACCESSWIREEvotec and CHDI Foundation Extend Strategic Drug Discovery Collaboration in Huntington’s Disease
Longstanding alliance between Evotec and CHDI to enable the development of therapeutics for Huntington's disease One of Evotec's largest strategic drug discovery alliances HAMBURG, GERMANY / ACCESSWIRE / May 28, 2024 / Evotec SE (Frankfurt Stock Exchange: ...
- ACCESSWIRE
Evotec Reports Q1 2024 Results and Provides Corporate Update
CHALLENGING Q1 WITH SOFTNESS MAINLY IN TRANSACTIONAL/DEVELOPMENT SHARED R&D BUSINESS AGAINST A STRONG COMPARABLE QUARTER STRONG START WITH JUST - EVOTEC BIOLOGICS IN Q1 2024 POSITIVE MOMENTUM IN SHARED R&D DISCOVERY CLOSED SALES POINT TO RECOVERY ...
- ACCESSWIRE
Evotec SE to Announce Results for First Quarter 2024 on 22 May 2024
HAMBURG, GERMANY / ACCESSWIRE / May 15, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for the first quarter of 2024 on Wednesday, 22 May 2024. The Company is going ...
